Dr. Sands on the Rationale to Explore DS-1062 in Advanced NSCLC

Video

In Partnership With:

Jacob Sands, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses the rationale to explore DS-1062 in advanced non–small cell lung cancer (NSCLC).

Jacob Sands, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses the rationale to explore DS-1062 in advanced non—small cell lung cancer (NSCLC).

At the 2019 ASCO Annual Meeting, Sands presented the safety and preliminary antitumor activity of DS-1062 in patients with advanced NSCLC. DS-1062 is a Trop-2-targeted antibody-drug conjugate (ADC). Trop-2 is a protein that is commonly seen on the surface of cancer cells. By targeting Trop-2 with an ADC, treatment can be delivered with less toxicity and more potency, explains Sands.

As a phase I dose-escalation trial, patients were started on relatively low doses of the drug. Among the 35 evaluable patients who received DS-1062, the dose levels ranged from 0.27 mg/kg to 8.0 mg/kg every 21 days. A total of 10 partial responses have been reported so far. These patients received a median of 3.5 prior lines of therapy, including prior EGFR or ALK inhibitors and checkpoint inhibitors.

Notably, patients were escalated beyond what researchers anticipated would be the maximum-tolerated dose, with a tolerability profile that has been consistent across doses, says Sands. However, higher response rates have been seen with higher doses of the drug. These data are very encouraging in a setting of high unmet need, Sands concludes.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD